Open Innovation Tackles NCDs in Africa
December 9, 2014 Editor
The Devex Impact website reported that to understand more about Africa’s increasing noncommunicable diseases (NCD) threat, we need to bring together the brightest scientific minds to work as a team rather than struggling alone to find answers. No single country in the region has enough researchers with the appropriate mix of skills required to tackle this challenge. GlaxoSmithKline is drawing on its research expertise to help kickstart the discovery of new and better treatments for NCDs. But its approach to tackling these diseases in Africa is turning the usual model of closely guarded research and development on its head with the establishment of the world’s first R&D “Open Lab” for NCDs in sub-Saharan Africa.
Click here to read the full article.
- Prevention and Management of Non-Communicable Disease: The IOC Consensus Statement, Lausanne 2013.
- No one size fits all! Lessons from legume–cereal rotations in smallholder farms
- The Pan-University Network for Global Health: framework for collaboration and review of global health needs.
- Let’s talk business: Knowledge-sharing helps make Sub-Saharan Africa more competitive
- Strategies to support non-communicable disease interventions
- Bio-enhanced Seeds: creating the next generation of seeds
Categories: Open Innovation
Subscribe to our stories
- Entrepreneurial Alertness, Innovation Modes, And Business Models in Small- And Medium-Sized Enterprises December 30, 2021
- The Strategic Role of Design in Driving Digital Innovation June 10, 2021
- Correction to: Hybrid mosquitoes? Evidence from rural Tanzania on how local communities conceptualize and respond to modified mosquitoes as a tool for malaria control June 10, 2021
- BRIEF FOCUS: Optimal spacing for groundnuts in smallholder farming systems June 9, 2021
- COVID-19 pandemic: impacts on the achievements of Sustainable Development Goals in Africa June 9, 2021